Perrigo (PRGO) Competitors $27.91 -0.16 (-0.57%) As of 02:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PRGO vs. CORT, JAZZ, SUPN, PCRX, NKTR, OMER, ASMB, CPIX, LLY, and JNJShould you be buying Perrigo stock or one of its competitors? The main competitors of Perrigo include Corcept Therapeutics (CORT), Jazz Pharmaceuticals (JAZZ), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Nektar Therapeutics (NKTR), Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), and Johnson & Johnson (JNJ). These companies are all part of the "pharmaceuticals" industry. Perrigo vs. Its Competitors Corcept Therapeutics Jazz Pharmaceuticals Supernus Pharmaceuticals Pacira BioSciences Nektar Therapeutics Omeros Assembly Biosciences Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson Perrigo (NYSE:PRGO) and Corcept Therapeutics (NASDAQ:CORT) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation. Is PRGO or CORT more profitable? Corcept Therapeutics has a net margin of 19.33% compared to Perrigo's net margin of -4.16%. Corcept Therapeutics' return on equity of 20.40% beat Perrigo's return on equity.Company Net Margins Return on Equity Return on Assets Perrigo-4.16% 8.93% 3.87% Corcept Therapeutics 19.33%20.40%16.64% Do institutionals and insiders believe in PRGO or CORT? 95.9% of Perrigo shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 0.4% of Perrigo shares are owned by insiders. Comparatively, 20.5% of Corcept Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer PRGO or CORT? Perrigo presently has a consensus price target of $33.00, indicating a potential upside of 18.24%. Corcept Therapeutics has a consensus price target of $138.25, indicating a potential upside of 99.70%. Given Corcept Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Corcept Therapeutics is more favorable than Perrigo.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Perrigo 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25Corcept Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer PRGO or CORT? In the previous week, Corcept Therapeutics had 11 more articles in the media than Perrigo. MarketBeat recorded 21 mentions for Corcept Therapeutics and 10 mentions for Perrigo. Corcept Therapeutics' average media sentiment score of 1.00 beat Perrigo's score of 0.86 indicating that Corcept Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perrigo 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Corcept Therapeutics 10 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Which has more risk & volatility, PRGO or CORT? Perrigo has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500. Which has preferable earnings and valuation, PRGO or CORT? Corcept Therapeutics has lower revenue, but higher earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPerrigo$4.37B0.88-$171.80M-$1.31-21.31Corcept Therapeutics$675.04M10.88$141.21M$1.1659.68 SummaryCorcept Therapeutics beats Perrigo on 13 of the 16 factors compared between the two stocks. Get Perrigo News Delivered to You Automatically Sign up to receive the latest news and ratings for PRGO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRGO vs. The Competition Export to ExcelMetricPerrigoMED PRODUCTS IndustryMedical SectorNYSE ExchangeMarket Cap$3.84B$10.44B$5.61B$20.89BDividend Yield4.12%1.91%4.71%3.60%P/E Ratio-21.3116.9527.9028.01Price / Sales0.8828.86392.4668.85Price / Cash5.5723.3936.3223.29Price / Book0.883.668.394.56Net Income-$171.80M$234.77M$3.25B$993.24M7 Day Performance-0.73%-1.82%-1.61%-1.58%1 Month Performance4.41%5.56%9.08%3.09%1 Year Performance-1.34%-13.62%35.49%9.26% Perrigo Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRGOPerrigo4.5303 of 5 stars$27.91-0.6%$33.00+18.2%+0.4%$3.84B$4.37B-21.318,379Upcoming EarningsCORTCorcept Therapeutics4.8211 of 5 stars$70.12-1.0%$138.25+97.2%+86.7%$7.44B$675.04M60.45300Positive NewsUpcoming EarningsJAZZJazz Pharmaceuticals4.8181 of 5 stars$112.65-0.2%$181.71+61.3%+4.9%$6.82B$4.07B15.022,800Positive NewsUpcoming EarningsSUPNSupernus Pharmaceuticals2.585 of 5 stars$33.23+2.8%$36.00+8.3%+9.3%$1.81B$668.00M29.94580News CoveragePositive NewsUpcoming EarningsAnalyst UpgradeGap UpPCRXPacira BioSciences3.2513 of 5 stars$22.17+2.7%$26.44+19.3%+6.2%$1.03B$700.97M-9.72720NKTRNektar Therapeutics4.0778 of 5 stars$24.79-0.6%$88.33+256.3%+12.3%$307.64M$98.43M-2.58220News CoveragePositive NewsUpcoming EarningsOMEROmeros3.7698 of 5 stars$3.64+8.3%$18.00+394.5%-26.2%$213.27MN/A-1.37210Positive NewsUpcoming EarningsASMBAssembly Biosciences3.7987 of 5 stars$18.25-2.3%$33.00+80.8%+26.4%$139.43M$28.52M-2.93100Upcoming EarningsCPIXCumberland Pharmaceuticals0.8895 of 5 stars$3.50+8.7%N/A+144.1%$52.36M$37.87M-14.0080Upcoming EarningsLLYEli Lilly and Company4.9836 of 5 stars$762.22-1.2%$1,012.56+32.8%-5.5%$722.39B$49.00B62.0247,000Trending NewsJNJJohnson & Johnson4.8287 of 5 stars$164.38+0.4%$172.87+5.2%+6.0%$395.51B$90.63B17.58138,100Positive NewsAnalyst Revision Related Companies and Tools Related Companies Corcept Therapeutics Competitors Jazz Pharmaceuticals Competitors Supernus Pharmaceuticals Competitors Pacira BioSciences Competitors Nektar Therapeutics Competitors Omeros Competitors Assembly Biosciences Competitors Cumberland Pharmaceuticals Competitors Eli Lilly and Company Competitors Johnson & Johnson Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PRGO) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredDrone Company Secures Major Defense Contract Amid Sweeping Policy ShiftOn July 10th, the White House and DoD announced a sweeping new directive to fast-track U.S. drone dominance. ...The Tomorrow Investor | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredNvidia’s next AI move could catch traders flat-footedTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thNew China tariffs hit August 12th—and Wall Street’s already moving. Banks and billionaires are quietly shif...American Alternative | SponsoredStrange Investment Secret Predicts Market's Next Move?A strange market signal discovered before the Great Depression has predicted nearly every major financial even...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perrigo Company plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Perrigo With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
